The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice

The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice Rationale Alcohol use disorders have become one of the most ethanol intake and preference in C57BL/6J mice treated with damaging psychiatric disorders in the world; however, there roflumilast (1, 3, or 10 mg/kg) or rolipram (0.5 mg/kg; posi- are no ideal treatments in clinic. Phosphodiesterase-4 (PDE4), tive control). The effect of roflumilast was verified using the an enzyme that specifically hydrolyzes intracellular cyclic ethanol drinking-in-dark (DID) test. Locomotor activity was AMP (cAMP), has been involved in alcohol use disorders. examined using the open-field test. Intake of sucrose or qui- Roflumilast is the first PDE4 inhibitor approved for treatment nine was also tested to determine whether natural reward pref- of chronic obstructive pulmonary diseases in clinic. It was of erence and aversive stimuli were involved in the effect of particular interest to researchers to determine whether PDE4 inhibitors. roflumilast altered ethanol consumption. Results Similar to rolipram, roflumilast decreased ethanol in- Objectives The present study tried to determine the effects of take and preference in two-bottle choice and DID tests in a roflumilast on ethanol intake and preference. dose-dependent manner, with significant changes at the dose of 10 mg/kg; in contrast, roflumilast did not affect sucrose or quinine drinking, although it http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice

Loading next page...
 
/lp/springer_journal/the-phosphodiesterase-4-inhibitor-roflumilast-decreases-ethanol-SCdaD0Qa0f
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Biomedicine; Neurosciences; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
D.O.I.
10.1007/s00213-017-4631-8
Publisher site
See Article on Publisher Site

Abstract

Rationale Alcohol use disorders have become one of the most ethanol intake and preference in C57BL/6J mice treated with damaging psychiatric disorders in the world; however, there roflumilast (1, 3, or 10 mg/kg) or rolipram (0.5 mg/kg; posi- are no ideal treatments in clinic. Phosphodiesterase-4 (PDE4), tive control). The effect of roflumilast was verified using the an enzyme that specifically hydrolyzes intracellular cyclic ethanol drinking-in-dark (DID) test. Locomotor activity was AMP (cAMP), has been involved in alcohol use disorders. examined using the open-field test. Intake of sucrose or qui- Roflumilast is the first PDE4 inhibitor approved for treatment nine was also tested to determine whether natural reward pref- of chronic obstructive pulmonary diseases in clinic. It was of erence and aversive stimuli were involved in the effect of particular interest to researchers to determine whether PDE4 inhibitors. roflumilast altered ethanol consumption. Results Similar to rolipram, roflumilast decreased ethanol in- Objectives The present study tried to determine the effects of take and preference in two-bottle choice and DID tests in a roflumilast on ethanol intake and preference. dose-dependent manner, with significant changes at the dose of 10 mg/kg; in contrast, roflumilast did not affect sucrose or quinine drinking, although it

Journal

PsychopharmacologySpringer Journals

Published: May 6, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off